David Schaffer, PhD

1993 Hertz Fellow
Find me on LinkedIn

David Schaffer is a professor of chemical and biomolecular engineering, bioengineering, and neuroscience at the University of California, Berkeley, where he also serves as the director of the California Institute for Quantitative Biosciences. David is also co-founder, chief scientist advisor and director of 4D Molecular Therapeutics.

In 1993, David graduated from Stanford University with a BS in chemical engineering. In 1998 he earned his PhD in chemical engineering at MIT. Finally, he did a postdoctoral fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in La Jolla, CA before moving to UC Berkeley in 1999. At Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.

David Schaffer has received an NSF CAREER Award, Office of Naval Research Young Investigator Award, Whitaker Foundation Young Investigator Award, and was named a Technology Review Top 100 Innovator. He also was awarded the Biomedical Engineering Society Rita Shaffer Young Investigator Award in 2000, the American Chemical Society BIOT Division Young Investigator Award in 2006, and was inducted into the College of Fellows of the American Institute of Medical and Biological Engineering in 2010.

Graduate Studies

Massachusetts Institute of Technology
Chemical Engineering, Bioengineering, Neuroscience
Epidermal Growth Factor Receptor-Mediated DNA Uptake: A Model System for Engineering Selective Gene Therapy Approaches

Undergraduate Studies

Stanford University

Related News

Mar 12, 2021
Hertz Fellow David Schaffer uses high throughput genetic sequencing technology to identify gene variants that can potentially help restore sight, repair hearts damaged by Fabry disease and improve lung function in patients with cystic fibrosis.

Related Events

e.image.alt
May 19, 2021
Innovation Hour
Hertz Fellow David Schaffer discusses advances in gene therapy using engineered adeno-associated viruses (AAVs) that enable a broad range of therapeutic applications.